Thioredoxin 1 plays a beneficial role in Alzheimer's disease by regulating endoplasmic reticulum stress

Author:

Xia Xun1,Xiao Jiujia1,Li Qinxuan1,Xiong Li1,Li Siyu1,Guo Chuan1

Affiliation:

1. Chengdu Medical College

Abstract

Abstract Alzheimer's disease (AD), a neurodegenerative disease, has a complex pathological mechanism involving oxidative stress, endoplasmic reticulum (ER) stress and other pathways. Thioredoxin 1 (Trx-1), the major redox regulator, may be an effective treatment strategy for AD. Therefore, the present study explored the role and possible mechanism of Trx-1 in AD. The expression of Trx-1 in the hippocampus of AD was verified by WB and RT-PCR, and the effects of Trx-1 on behavioral function and neuropathological damage of AD mice were analyzed by open field test, water maze experiment, HE staining, and protein expression analysis of amyloid β-protein (Aβ), Tau protein (Tau) and p-Tau. At the same time, oxygen species (ROS) and ER stress were detected to further analyze the mechanism. Trx-1 expression in the hippocampus of AD model mice was reduced, and the oe-Trx-1 remarkably enhanced it. We observed an obvious behavioral cognitive dysfunction and neuropathological damage in AD model mice. Trx-1 significantly ameliorated the anxiety-like behavior and cognitive ability in AD mice, alleviated the pathological damage of hippocampal tissue, and reduced the protein expressions of Aβ, Tau, and p-Tau, suggesting that Trx-1 could alleviate behavioral cognitive dysfunction and neuropathological damage in AD. In addition, Trx-1 significantly reduced ROS levels and the GRP78, PERK, IRE1α, and CHOP protein expression and relieved ER stress in AD mice. Trx-1 may alleviate behavioral cognitive dysfunction and neuropathological damage in AD mice by regulating ER stress.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Alzheimer's disease;Soria Lopez JA;Handb Clin Neurol,2019

2. The prevalence of Alzheimer's disease in the Chinese Han population: a meta-analysis;Zhao X;Neurol Res,2020

3. Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res. 2018; 7.

4. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014;Schneider LS;J Intern Med,2014

5. Drug treatments in Alzheimer's disease;Briggs R;Clin Med (Lond),2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3